Archive

Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis.

At month 12, median triglyceride fell 79% and 81% with plozasiran; placebo-adjusted difference -45 and -47 percentage points. Acute pancreatitis rates were 1 versus 5 per 100 patient-years (rate ratio 0.22; P=0.008).

Endocrinology · NEJM · 9h

Adrenal Crisis Associated With Graves' Disease Relapse After Levothyroxine Reintroduction in Established Autoimmune Polyglandular Syndrome Type 2: A Case Report and Review of Thyroid-Adrenal Interactions

Two months after being euthyroid with negative thyroid-stimulating immunoglobulins, subclinical hypothyroidism led to levothyroxine 50 µg/day; one month later she had adrenal crisis with hyponatremia, mild hyperkalemia, elevated ACTH and overt thyrotoxicosis with TSI.

Endocrinology · Cureus · 22h

Weight-loss injections are not PMOS cure; experts caution against self-medication

GLP-1s alone won't treat PCOS; individualise by metabolic and fertility goals and warn patients off self-sourcing these drugs for weight loss.

Endocrinology · ETHealthworld · 3d

Pioglitazone-Mediated Reduction of Ectopic Fat in Metabolic Dysfunction-Associated Steatotic Liver Disease

Pioglitazone shifts fat out of liver and viscera into subcutaneous stores, so it can improve steatosis and insulin resistance in MASLD — but weigh weight gain and fluid retention.

Endocrinology · Cureus · 4d

Codeine-Associated Secondary Adrenal Insufficiency: A Case Report

Before labelling unexplained fatigue and low cortisol as primary adrenal failure, ask about chronic codeine use — it can suppress ACTH and mimic hypopituitarism.

Endocrinology · Cureus · 5d

Associations of Age, Sex, and Diabetes Duration With Sensorineural Hearing Loss Severity in Patients With Type 2 Diabetes Mellitus: A Retrospective Study

Longer diabetes duration and older age track with worse hearing loss, so consider audiometry in long-standing T2DM patients who report hearing difficulty.

Endocrinology · Cureus · 6d

Evaluating an Outpatient Rapid Preoperative Optimization Protocol for Poorly Controlled Graves’ Disease: A Retrospective Cohort Study

A structured outpatient protocol may shorten the 4-8 week thionamide wait before thyroidectomy, reducing thyroid storm risk in poorly controlled Graves' patients.

Endocrinology · Cureus · 6d

Twelve-Month Albuminuria Response to Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus: A Real-World Study

Real-world Indian data showing finerenone lowers albuminuria over 12 months supports adding it to RAS blockade in your diabetic CKD patients, including those with heavy baseline proteinuria.

Endocrinology · Cureus · 6d

Short-Term Glycemic Response to Tirzepatide According to Prior Incretin Therapy in Patients with Type 2 Diabetes Mellitus

Prior incretin exposure may blunt tirzepatide's HbA1c drop at three months, so set expectations and review timing when switching GLP-1-experienced patients.

Endocrinology · Cureus · 6d

Oura, UC San Diego Health collaborate to study GLP-1 outcomes using continuous smart ring data

If ring-derived sleep and activity data predict GLP-1 response, you may soon titrate obesity therapy using objective adherence and physiological signals rather than weight alone.

Endocrinology · Fierce Healthcare · 8d

Adalimumab-Associated Thyroiditis in a Patient With Pre-existing Hypothyroidism: A Case Report and Literature Review

Meningitis was excluded on CSF analysis and neuroimaging; thyroid imaging showed thyroiditis with reactive lymphadenopathy, anti-TPO antibodies were elevated, and thyroid hormone levels stayed within the reference range. Corticosteroids gave significant symptomatic improvement.

Endocrinology · Cureus · 8d

Counsel Health launches AI-native weight management program, inks partnership with Lilly Direct

An AI-run weight program tied to Lilly Direct could become a referral and prescribing channel your obese patients encounter before they reach you.

Endocrinology · Fierce Healthcare · 9d

Metabolic heterogeneity of obesity.

Two patients at the same BMI can differ sharply in insulin sensitivity, so stratify by metabolic markers rather than weight alone before escalating therapy.

Endocrinology · Nature Medicine · 9d

Magnesium Status and Its Association With Glycemic Control and Diabetes-Related Complications in Type 2 Diabetes Mellitus: A Systematic Review

Lower magnesium status was commonly associated with higher HbA1c and glucose, greater insulin resistance, and retinopathy, neuropathy, nephropathy and vascular disease. The single randomised trial raised serum magnesium without improving insulin sensitivity or glycaemic outcomes.

Endocrinology · Cureus · 10d

Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Explains the small but consistent hemoglobin rise on SGLT2 inhibitors — useful when interpreting falling or stable counts in diabetic and heart-failure patients already on these drugs.

Endocrinology · JAMA · 12d

Remote Endocrinology Support for Primary Care Clinicians Managing Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials

Evidence on remote specialist support for primary-care diabetes care is still uncertain, so don't assume e-consult or tele-endocrinology models improve HbA1c until trials show it.

Endocrinology · Cureus · 13d

Subclinical Hypothyroidism: Who Should Be Treated and Who Can Be Observed?

Most SCH is transient and TSH under 10 rarely needs levothyroxine; repeat TSH in 6-8 weeks before prescribing, and treat if pregnant, symptomatic or TSH rising.

Endocrinology · Cureus · 21 Oct

Efficacy and Safety of Automated Insulin Delivery Systems in Children and Adolescents With Type 1 Diabetes: A Systematic Review of Randomized Controlled Trials

Time in range improved by roughly 7 to 12 percentage points across trials; one showed 11 points (95% CI 7-14) and another 8.7 points (95% CI 7.4-9.9) with a 0.4-point HbA1c fall. Hypoglycaemia did not consistently increase.

Endocrinology · Cureus · 21 Oct

As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags

Ask GLP-1 patients about supplement use — unregulated products marketed for weight loss carry interaction and contamination risks your prescription review won't catch.

Endocrinology · ETHealthworld · 21 Oct

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Adolescents With Obesity: A Retrospective Study

Mean reductions at 32 weeks: body weight -15.20 kg (17.2%), BMI -6.70 kg/m² (19.4%), BMI-SDS -1.08, waist circumference -10.71 cm, systolic BP -8.30 mmHg; glycaemic and lipid parameters also improved (all p < 0.001). No adverse events documented.

Endocrinology · Cureus · 21 Oct

Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.

A triple agonist injection may cut OSA severity in patients who cannot tolerate CPAP — worth knowing before patients ask about it.

Endocrinology · NEJM · 21 Oct

Pituicytoma Presenting With Hypogonadotropic Hypogonadism in a Highly Vascular Sellar and Suprasellar Mass: A Case Report

Total testosterone was 8.9 nmol/L with inappropriately normal LH and FSH. CT angiography showed a hypertrophied right meningo-hypophyseal trunk; only partial debulking was possible, and histopathology confirmed pituicytoma

Endocrinology · Cureus · 19 Oct

Knowledge, Attitudes, and Use of Antidiabetic Medications for Weight Loss Among Adults in Riyadh, Saudi Arabia: A Cross-Sectional Study

76 participants (27.0%) reported using antidiabetic medications for weight loss, mostly Ozempic (55.3%) and Mounjaro (44.7%). Median knowledge score 15.0 (IQR 12.0-18.0); knowledge-attitude correlation weak (Spearman's rho = 0.254, p < 0.001).

Endocrinology · Cureus · 19 Oct

Cryoablation in Thyroid Nodules: Current Evidence, Technical Considerations, and Clinical Applications

Benign nodules: technical success in all, no moderate or severe adverse events, mean volume reduction 42.3%, 65.4%, 68.4% and 63.7% at 1, 3, 6 and 12 months. Papillary cancer: moderate adverse events in 3%, no recurrence over mean 34.8 months.

Endocrinology · Cureus · 19 Oct

Food Noise in Obesity: Current Evidence, Measurement, and Clinical Implications

Patients on GLP-1 agonists often report silencing of intrusive food thoughts; this review helps you name and assess that symptom rather than dismiss it as vague craving.

Endocrinology · Cureus · 18 Oct

When Appearances Deceive: A Silent Somatotroph Macroadenoma Presenting With Acromegaloid Features and Paradoxically Low Insulin-Like Growth Factor-1

Acromegaloid features with low IGF-1 can still be a GH-expressing macroadenoma; don't let normal biochemistry delay pituitary imaging in a patient with cranial nerve palsy.

Endocrinology · Cureus · 18 Oct

Predictors of Successful Prandial Insulin Withdrawal Following the Initiation of Therapy Based on Glucagon-Like Peptide-1 (GLP-1) in Adults With Type 2 Diabetes (T2D): A Systematic Review of Clinical, Biochemical, and Treatment-Related Factors

If you start a GLP-1 in a basal-bolus patient, this maps which clinical and biochemical features predict safely dropping mealtime insulin rather than guessing.

Endocrinology · Cureus · 17 Oct

Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women.

Digital-first GLP-1RA prescribing achieved real-world weight loss in 8,127 women, mostly tirzepatide — evidence you can cite when patients ask whether app-based obesity care actually works.

Endocrinology · Nature Medicine · 16 Oct

Continuous Glucose Monitoring in Non-Insulin-Treated Type 2 Diabetes.

CGM improved glycaemic control in non-insulin-treated type 2 diabetes managed in primary care, supporting wider use beyond insulin-treated patients.

Endocrinology · NEJM · 14 Oct

Obesity tops global health threats by avoidable burden: Lancet Commission

Obesity now outranks other modifiable risks in avoidable DALYs, so weight management deserves the same clinical priority as hypertension and smoking cessation in your practice.

Endocrinology · ETHealthworld · 12 Oct

FSSAI pulls up Dr Reddy's, Nestle Health Science over Celevida claims

If patients on GLP-1 therapy ask about high-protein supplements like Celevida, know the muscle-preservation claims are now contested by FSSAI.

Endocrinology · ETHealthworld · 9 Oct

Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial.

An oral GLP-1 agonist needing no fasting or diet rules could give your type 2 patients injectable-level glycaemic control with a tablet.

Endocrinology · Nature Medicine · 5 Oct

Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.

Semaglutide 1 mg weekly preserved kidney function over 52 weeks in T2D with CKD, supporting a GLP-1 option alongside SGLT2 inhibitors for renal protection.

Endocrinology · Nature Medicine · 1 Oct

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

A dual GLP-1/glucagon agonist may offer added weight and glycaemic benefit over current GLP-1 agonists in patients with obesity and type 2 diabetes.

Endocrinology · NEJM · 1 Oct

When Diabetes Mimics Scleroderma: Cheiroarthropathy and Neuropathic Digital Erosions in Type 2 Diabetes

In long-standing diabetes with waxy, stiff hands, consider cheiroarthropathy before labelling scleroderma — it spares patients unnecessary rheumatology workup and immunosuppression.

Endocrinology · Cureus · 1 Oct

Timing of Growth Hormone Therapy Initiation and Final Adult Height in Idiopathic Short Stature: A Systematic Review

Largest registry analysis of 3,939 prepubertal children found no significant mean gain in near-adult height SDS in the ISS subgroup; late-pubertal cohorts reported final heights of 170.9-173.5 cm in males.

Endocrinology · Cureus · 30 Sept

Preserving Muscle Health During Weight Loss: Evidence Across Lifestyle, Surgical, and Pharmacological Interventions

Caloric restriction reduced weight and fat mass but caused variable fat-free mass loss; greater energy restriction sometimes meant greater lean loss. Higher protein plus resistance exercise best preserved lean tissue. Lean mass loss did not necessarily impair strength or function.

Endocrinology · Cureus · 30 Sept

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Offers an oral GLP-1 option for type 2 diabetes patients at cardiovascular risk, though it only matches insulin glargine rather than reducing events.

Endocrinology · Lancet · 30 Sept

Recurrent Facial Miliaria Crystallina Revealing Underlying Hyperthyroidism: A Report of Two Cases

Recurrent facial miliaria without heat or fever triggers should prompt thyroid function testing, as both reported cases had underlying hyperthyroidism.

Endocrinology · Cureus · 29 Sept

Iatrogenic Cushing Syndrome With Glucocorticoid-Induced Adrenal Insufficiency Following Prolonged Topical Clobetasol Use in an Adolescent

Morning cortisol <30 nmol/L, ACTH <5 ng/L; Synacthen cortisol <30 nmol/L at baseline and 30 minutes, 38 nmol/L at 60 minutes. Adrenal reserve recovered by seven months after stopping clobetasol.

Endocrinology · Cureus · 29 Sept